Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registryVince Biemans, Andrea E. van der Meulen‐de Jong, Nanne K.H. de Boer et al.|Alimentary Pharmacology & Therapeutics|2020Cited by 87
Effectiveness and safety of tofacitinib for ulcerative colitis: two‐year results of the ICC RegistryTessa Straatmijer, Marjolijn Duijvestein, Fiona D M van Schaik et al.|Alimentary Pharmacology & Therapeutics|2022Cited by 28
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trialReinier C A van Linschoten, Aura A. J. van Esch, Fenna M. Jansen et al.|The Lancet. Gastroenterology & hepatology|2023Cited by 21
Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn’s Disease Patients in Stable Remission: The Randomized Controlled LADI TrialFenna M. Jansen, Aura A. J. van Esch, Reinier C A van Linschoten et al.|Journal of Crohn s and Colitis|2023Cited by 4
Tu1892 TOFACITINIB FOR ULCERATIVE COLITIS: RESULTS OF THE ICC REGISTRY, A NATIONWIDE PROSPECTIVE OBSERVATIONAL COHORT STUDYVince Biemans, Jasmijn A M Sleutjes, Annemarie C. de Vries et al.|Gastroenterology|2020Cited by 1